右美托咪定对麻醉后监护室离院与恢复的影响:系统综述与荟萃分析
该系统综述纳入33项随机对照研究共2676例非心脏非神经外科全麻成人患者,评估右美托咪定对PACU停留时间及恢复的影响。右美托咪定未显著增加PACU停留时间(MD 0.69分钟,95%CI -1.42至2.81),但降低躁动、咳嗽、疼痛、术后恶心呕吐和寒战发生率,低血压发生率增加。
要点
- 右美托咪定不延长PACU停留时间,但降低躁动、咳嗽、疼痛、恶心呕吐和寒战。
- 右美托咪定增加低血压风险(RR 5.39),不增加残余镇静或心动过缓。
- 拔管时间延长1分钟,无临床意义。
核心结论
- 右美托咪定不增加PACU停留时间,降低躁动、咳嗽、疼痛、术后恶心呕吐和寒战发生率,但增加低血压发生率,不增加残余镇静或心动过缓。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、PubMed和Cochrane Library至2021年3月31日,纳入33项随机对照研究共2676例成人非心脏非神经外科全麻患者。
- 研究方案注册于PROSPERO(CRD42021240559),无特定资助。
主要发现
- 右美托咪定组PACU停留时间无显著增加(MD 0.69分钟,95%CI -1.42至2.81)。
- 拔管时间有统计学但非临床显著延长(MD 1分钟,95%CI 0.32至1.68)。
- 躁动(RR 0.38,95%CI 0.29-0.52)、咳嗽(RR 0.69,95%CI 0.61-0.79)、疼痛(RR 0.50,95%CI 0.32-0.80)、术后恶心呕吐(RR 0.54,95%CI 0.33-0.86)和寒战(RR 0.24,95%CI 0.12-0.49)发生率显著降低。
- 低血压发生率增加(RR 5.39,95%CI 1.12-5.89),残余镇静(RR 1.23,95%CI 0.20-7.56)和心动过缓(RR 5.13,95%CI 0.96-27.47)无显著增加。
临床怎么用
- 围术期使用右美托咪定可改善PACU恢复质量,不延长停留时间,但需警惕低血压。
局限性
- 所有研究总体偏倚风险为低风险或有一些担忧,证据确定性为低至高质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current evidence on the effect of dexmedetomidine in early postoperative recovery is limited. We conducted a systematic review to evaluate the effect of dexmedetomidine on the length of stay (LOS) and recovery profile in postanesthesia care unit (PACU) patients. METHODS: The study protocol is registered on International Prospective Register of Systematic Reviews (PROSPERO; CRD42021240559). No specific funding or support was received. We conducted searches in MEDLINE, Embase, PubMed, and Cochrane Library to March 31, 2021 for peer-reviewed randomized controlled studies comparing adult patients who received intravenous dexmedetomidine and placebo undergoing noncardiac, nonneurosurgical procedures under general anesthesia. All studies reporting statistics relating to the duration of stay in the recovery ward or PACU, the primary outcome, were included. We performed individual random-effect meta-analysis on the primary and secondary outcomes (time to extubation, emergence agitation, cough, pain, postoperative nausea and vomiting, shivering, residual sedation, bradycardia, and hypotension) using Stata version 17.0. Evidence was synthesized as mean difference (MD) and risk ratio (RR) for continuous and dichotomous variables, respectively. The quality of evidence was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) tool and Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Thirty-three studies including 2676 patients were eligible for analysis. All studies had low risk or some concerns of overall bias and provided low-to-high certainty evidence for all studied outcomes. Dexmedetomidine was not associated with a significantly increased PACU LOS (MD, 0.69 minute; 95% confidence interval [CI], -1.42 to 2.81 minutes). It was associated with a statistically but not clinically significant prolonged time to extubation (MD, 1 minute; 95% CI, 0.32-1.68 minutes). Dexmedetomidine was associated with significantly reduced incidence of emergence agitation (RR, 0.38; 95% CI, 0.29-0.52), cough (RR, 0.69; 95% CI, 0.61-0.79), pain (RR, 0.50; 95% CI, 0.32-0.80), postoperative nausea and vomiting (RR, 0.54; 95% CI, 0.33-0.86), and shivering (RR, 0.24; 95% CI, 0.12-0.49) in PACU. There was an increased incidence of hypotension (RR, 5.39; 95% CI, 1.12-5.89) but not residual sedation (RR, 1.23; 95% CI, 0.20-7.56) or bradycardia (RR, 5.13; 95% CI, 0.96-27.47) in the dexmedetomidine group. CONCLUSIONS: The use of dexmedetomidine did not increase the duration of PACU LOS but was associated with reduced emergence agitation, cough, pain, postoperative nausea and vomiting, and shivering in PACU. There was an increased incidence of hypotension but not residual sedation or bradycardia in PACU.
引用
- Sin JCK, Tabah A, Campher MJJ, et al. The Effect of Dexmedetomidine on Postanesthesia Care Unit Discharge and Recovery: A Systematic Review and Meta-Analysis. Anesth Analg. 2022. PMID: 35085107. doi:10.1213/ANE.0000000000005843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。